Abstract: Novel 18F-labelled tetrazines are provided which are highly reactive to be effective in vivo, suitable for pretargeted positron emission tomography (PET) and accessible in radiochemical yields (RCYs) which allow access to 18F-labeled tetrazines for clinical applications. The 18F-labelled tetrazines are developed using a Cu-mediated click indirect labelling approach. Only a subset of compounds appeared to be suitable for clinical pretargeted imaging strategies, and a particular compound which includes the use of an 18F-labelled azide synthon having an azide structure with glucose as the linker and a triazole moiety within the linker, appears to be highly suited for clinical pretargeted imaging purposes.

Abstract: The present disclosure provides bioorthogonal linkers and reagents, including trans-cyclooctene (“TCO”)- and tetrazine (“Tz”)-containing compounds. In a general aspect, the present disclosure provides reagents, conjugates, and bioactive molecules containing a trans-cyclooctene (“TCO”) fragment. Examples of TCO fragments include: Formulae (I) and (II).

Abstract: The invention disclosed herein relates to compounds, combinations, kits, and methods using same, for use in bioorthogonal release reactions. In particular, the compounds, combinations and kits of the invention can be used to achieve fast and efficient click release. Applications of the compounds, combinations, and kits of the invention include both in vitro and in vivo applications.

Abstract: System (100) comprising a device (101) comprising a body (102), an ion conductive member (120), a first electrode (131), and a second electrode (132). The system (100) further comprises a source solution (141), a target solution (142), a first species (151), and a second species (152). A first end (121) of the ion conductive member (120) is arranged in contact with 5 the source solution (141). A second end (122) of the ion conductive member (120) is arranged in contact with the target solution (142). The first electrode (131) is arranged in contact with the source solution (141), the second electrode (132) is arranged in contact with the target solution (142), the first species (151) is in the source solution (141), and the second species (152) is in the target solution (142).

Abstract: Novel 18F-labelled tetrazines are provided which are highly reactive to be effective in vivo, suitable for pretargeted positron emission tomography (PET) and accessible in radiochemical yields (RCYs) which allow access to 18F-labeled tetrazines for clinical applications. The 18F-labelled tetrazines are developed using a Cu-mediated click indirect labelling approach. Only a subset of compounds appeared to be suitable for clinical pretargeted imaging strategies, and a particular compound which includes the use of an 18F-labelled azide synthon having an azide structure with glucose as the linker and a triazole moiety within the linker, appears to be highly suited for clinical pretargeted imaging purposes.

Abstract: The present application provides a compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein L1, L2, L3, n, m, p, X, T, TR, and D are as described herein. Methods of using of these compounds to treat diseases advantageously treatable by drug D are also described.